CN102406754B - Chinese medicinal composition for treating chronic heart failure - Google Patents
Chinese medicinal composition for treating chronic heart failure Download PDFInfo
- Publication number
- CN102406754B CN102406754B CN201110384119XA CN201110384119A CN102406754B CN 102406754 B CN102406754 B CN 102406754B CN 201110384119X A CN201110384119X A CN 201110384119XA CN 201110384119 A CN201110384119 A CN 201110384119A CN 102406754 B CN102406754 B CN 102406754B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- heart failure
- chinese medicine
- chronic heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims abstract description 11
- 241000222336 Ganoderma Species 0.000 claims abstract description 8
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 7
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 23
- 241000628997 Flos Species 0.000 claims description 6
- 210000001320 hippocampus Anatomy 0.000 claims description 6
- 241001633583 Adenophora Species 0.000 claims description 2
- 241001446509 Psoralea Species 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 230000007812 deficiency Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 241001412627 Adenophora liliifolia Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241001487912 Coralliozetus angelicus Species 0.000 abstract 1
- 244000241463 Cullen corylifolium Species 0.000 abstract 1
- 241000096284 Gynochthodes officinalis Species 0.000 abstract 1
- 241001559542 Hippocampus hippocampus Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 208000031975 Yang Deficiency Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 description 9
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 208000015210 hypertensive heart disease Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241000213006 Angelica dahurica Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940085034 digoxin 0.25 mg Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940082205 hydrochlorothiazide 25 mg Drugs 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229940093252 sorbitrate Drugs 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000005092 tracheal tissue Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating the chronic heart failure. In the traditional Chinese medical science, the chronic heart failure is generated due to weak qi, defect of blood transportation caused by weak qi, heart-yin loss and deficiency of yin and astringent blood and shows as yin-yang deficiency, unsmooth heart and nutriment and stasis retention in the heart vessels. Therefore, traditional Chinese medicines capable of supplementing qi to warm yang and activating blood and dredging collaterals, i.e. angelica sinensis, safflower, red paeony root, malaytea scurfpea fruit, morinda officinalis, lucid ganoderma, seahorse, caulis spatholobi, arillus longan, ladybell root, rhizoma atractylodis macrocephalae and raw rehmannia glutinosa, are selected to be prepared into decoction; and after the decoction is administrated to a patient, a good treatment effect is obtained. By clinical tests of the hospital, the total effective rate of the Chinese medicinal preparation reaches 93.8 percent. Moreover, the Chinese medicinal preparation has small toxic or side effects and is valuable to be clinically popularized and applied.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, relate in particular to a kind of Chinese medicine preparation of chronic heart failure.
Background technology
Heart failure is a kind of clinical syndrome of complexity, it is the syndrome that various heart diseases cause cardiac insufficiency, that myocardial contraction descends in most cases, make cardiac output can not satisfy the needs of organism metabolism, tracheal tissue's hemoperfusion is not enough, occur simultaneously the lung stasis of blood and (or) performance of body circulation blood stasis, be the final result that multiple makings heart disease may be avoided hardly.Be more common in coronary heart disease, hypertensive heart disease and cardiomyopathy expansion.In case form, mostly be repeatedly outbreak and increase the weight of gradually, the treatment difficulty is large, and fatality rate is high.Though western medicine has been obtained certain effect, but prolonged application has certain side effect, such as diuretic and vasodilation and the inotropic agent that adopts in the treatment, often because the side effects clinical practices such as poisoning, electrolyte disturbance occurring, and often need the multi-medicament use in conjunction.The advantages such as at present, and Chinese medicine heart failure such as side effect is less, and curative effect is lasting.
Summary of the invention
The Chinese medicine composition that the purpose of this invention is to provide a kind of chronic heart failure.The traditional Chinese medical science think the primary disease pathogeny then many because of a little less than the deficiency of vital energy, that gas is not transported blood, the heart-yin loss, deficiency of YIN blood is puckery, shows as that deficiency of both YIN and YANG, the heart-nutriment are smooth, the heart arteries and veins stasis of blood stagnates.In the treatment with QI invigorating warming YANG medicine for control network this, be aided with circulation promoting vein relaxing medicine, make the prosperous blood ruton of gas, the pathology link of blocking-up blood stasis network resistance has edema-alleviating diuretic concurrently to control its mark.
The objective of the invention is to be achieved through the following technical solutions, the Chinese medicine composition of this chronic heart failure is made by the Chinese medicine of following weight portion: Radix Angelicae Sinensis 10-15 part, Flos Carthami 9-13 part, Radix Paeoniae Rubra 12-16 part, Fructus Psoraleae 10-15 part, Radix Morindae Officinalis 15-20 part, Ganoderma 15-20 part, Hippocampus 9-13 part, Caulis Spatholobi 12-16 part, Arillus Longan 10-15 part, Radix Adenophorae 9-13 part, Rhizoma Atractylodis Macrocephalae 7-11 part, Radix Rehmanniae 8-12 part.
Preferably, the Chinese medicine composition of this chronic heart failure is made by the Chinese medicine of following weight portion: 13 parts of Radix Angelicae Sinensis, 11 parts on Flos Carthami, 14 parts of Radix Paeoniae Rubra, 13 parts of Fructus Psoraleaes, 17 parts of Radix Morindae Officinaliss, 17 parts of Ganodermas, 11 parts of Hippocampus, 14 parts of Caulis Spatholobis, 13 parts of Arillus Longans, 11 parts of Radix Adenophoraes, 9 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Rehmanniae.
Getting above Chinese medicine makes decoction by traditional preparation method and gets final product.
In the side: Flos Carthami invigorate blood circulation latus rectum, eliminating stasis to stop pain; The pain relieving of Radix Paeoniae Rubra clots absorbing, the removing heat from blood detumescence; The Fructus Psoraleae reinforcing the kidney and supporting YANG, helping inspiration to relieve asthma, warming spleen and stopping diarrha; The Radix Morindae Officinalis kidney-replenishing, bone and muscle strengthening, wind-damp dispelling; The Hippocampus mass dissipating and swelling eliminating, warming and recuperating the kidney-YANG; Caulis Spatholobi is enriched blood and invigorates blood circulation, dredging the meridian; The Arillus Longan invigorating the heart and spleen, nourishing blood to tranquillize the mind; Chinese angelica blood supplementing is invigorated blood circulation, menstruction regulating and pain relieving; The Radix Adenophorae QI invigorating of reducing phlegm, the lung moistening stomach function regulating; Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, hidroschesis is antiabortive; The Radix Rehmanniae clearing away heat and promoting production of body fluid, yin nourishing is nourished blood; The Ganoderma blood yiqi; zoopery and clinical trial all show; Ganoderma is coronary artery dilator effectively; increase coronary flow; improve Myocardial Microcirculation, strengthen the supply of myocardium oxygen and energy, therefore; myocardial ischemia is had protective effect, can be widely used in treatment and the prevention of coronary heart diseases and angina pectoris etc.
Clinical data
1, physical data whole 160 routine patients come from the court's inpatient in March, 2007～October.Be divided at random treatment group and matched group, treatment group 80 examples, male 47 examples wherein, women 33 examples, 45 ± 4.5 years old age; Coronary heart disease 35 examples, hypertensive heart disease 29 examples, dilated cardiomyopathy 16 examples; NYHA III～IV level 59 examples.Matched group 80 examples, male 45 examples wherein, women 35 examples, 43 ± 4.8 years old age; Coronary heart disease 34 examples, hypertensive heart disease 30 examples, dilated cardiomyopathy 16 examples; NYHA III～IV56 example.Two groups of sexes, age, sickly plant, the severity of heart failure no significant difference, have comparability.
2, inclusion criteria: the heart failure that coronary heart disease, hypertension, dilated cardiomyopathy cause, NYHA II～IV level; Left Ventricular Ejection Fraction≤40%.Reject: valvular heart disease, the pregnant woman once participated in the other drug clinical research in 1 month, and patient that can not be oral is reluctant the patient of reception test.
3, two groups of patients of Therapeutic Method are according to the concrete state of an illness, and conventional application digoxin 0.25mg is oral, 1 time/d; Hydrochlorothiazide 25mg is oral, 2 times/d; Sorbitrate 10mg is oral, and 3 times/d, diuretic is taken 7d and then stopped.Treatment group adds uses Chinese medicine composition of the present invention: Radix Angelicae Sinensis 13g, Flos Carthami 11g, Radix Paeoniae Rubra 14g, Fructus Psoraleae 13g, Radix Morindae Officinalis 17g, Ganoderma 17g, Hippocampus 11g, Caulis Spatholobi 14g, Arillus Longan 13g, Radix Adenophorae 11g, Rhizoma Atractylodis Macrocephalae 9g, Radix Rehmanniae 10g, 1 dose/d, decoction 300mL, each 100mL is oral, 3 times/d.Stopping using and expand blood vessel and regulate neuroendocrine hormone medicine in two groups of bases in tight observation, assurance safety, adds up curative effect after 1 month.
4, the time that the change of observation index heart failure symptoms and sign, heart failure take a turn for the better.
5, curative effect judging standard cardiac function (NYHA) improves that the person is produce effects more than 2 grades; It is effective improving 1 grade; Be invalid without improvement or deterioration, died.
6, therapeutic outcome
1. two groups of cardiac function efficacy analysis
Treatment group produce effects 49 examples (61.3%), effective 26 examples (32.5%), invalid 5 examples (6.3%), total effective rate is 93.8%; Matched group produce effects 35 examples (43.8%), effective 30 examples (37.5%), invalid 15 examples (18.8%), total effective rate is 81.3%.Two groups of total effective rates relatively have significant difference.
2. two groups of heart failure improvement times, hospital stayss are analyzed
Treatment group heart failure improvement time, hospital stays were respectively 5.5 ± 1.5 days, 9.8 ± 2.5 days; Matched group was respectively 7.1 ± 2.6 days, 13.6 ± 1.6 days.Two groups of two index comparing differences have highly significant (P all＜0.01).
Claims (2)
1. the Chinese medicine composition of a chronic heart failure is characterized in that the Chinese medicine composition of this chronic heart failure is made by the Chinese medicine of following weight portion: Radix Angelicae Sinensis 10-15 part, Flos Carthami 9-13 part, Radix Paeoniae Rubra 12-16 part, Fructus Psoraleae 10-15 part, Radix Morindae Officinalis 15-20 part, Ganoderma 15-20 part, Hippocampus 9-13 part, Caulis Spatholobi 12-16 part, Arillus Longan 10-15 part, Radix Adenophorae 9-13 part, Rhizoma Atractylodis Macrocephalae 7-11 part, Radix Rehmanniae 8-12 part.
2. the Chinese medicine composition of a kind of chronic heart failure according to claim 1 is characterized in that this Chinese medicine composition made by the Chinese medicine of following weight portion: 13 parts of Radix Angelicae Sinensis, 11 parts on Flos Carthami, 14 parts of Radix Paeoniae Rubra, 13 parts of Fructus Psoraleaes, 17 parts of Radix Morindae Officinaliss, 17 parts of Ganodermas, 11 parts of Hippocampus, 14 parts of Caulis Spatholobis, 13 parts of Arillus Longans, 11 parts of Radix Adenophoraes, 9 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Radix Rehmanniae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110384119XA CN102406754B (en) | 2011-11-18 | 2011-11-18 | Chinese medicinal composition for treating chronic heart failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110384119XA CN102406754B (en) | 2011-11-18 | 2011-11-18 | Chinese medicinal composition for treating chronic heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102406754A CN102406754A (en) | 2012-04-11 |
| CN102406754B true CN102406754B (en) | 2013-03-20 |
Family
ID=45909291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110384119XA Active CN102406754B (en) | 2011-11-18 | 2011-11-18 | Chinese medicinal composition for treating chronic heart failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102406754B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105596715A (en) * | 2016-02-16 | 2016-05-25 | 四川双鑫生物科技有限公司 | Decoction medicine for treating chronic cardiac failure and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (en) * | 2001-01-14 | 2001-08-01 | 刘红 | Medicine for treating congestive heart failure |
| CN1970069A (en) * | 2006-12-26 | 2007-05-30 | 曹国胜 | Chinese medicinal pill for treating coronary heart disease |
| CN101524521A (en) * | 2008-03-07 | 2009-09-09 | 天科仁祥技术（北京）有限责任公司 | Chinese medicinal composition for treating coronary heart disease and preparation method thereof |
| CN101524469A (en) * | 2009-04-17 | 2009-09-09 | 山东大学齐鲁医院 | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof |
| CN101584805A (en) * | 2009-06-29 | 2009-11-25 | 河北惟祥福中药科技开发有限公司 | Chinese medicine preparation for treating heart failure |
-
2011
- 2011-11-18 CN CN201110384119XA patent/CN102406754B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (en) * | 2001-01-14 | 2001-08-01 | 刘红 | Medicine for treating congestive heart failure |
| CN1970069A (en) * | 2006-12-26 | 2007-05-30 | 曹国胜 | Chinese medicinal pill for treating coronary heart disease |
| CN101524521A (en) * | 2008-03-07 | 2009-09-09 | 天科仁祥技术（北京）有限责任公司 | Chinese medicinal composition for treating coronary heart disease and preparation method thereof |
| CN101524469A (en) * | 2009-04-17 | 2009-09-09 | 山东大学齐鲁医院 | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof |
| CN101584805A (en) * | 2009-06-29 | 2009-11-25 | 河北惟祥福中药科技开发有限公司 | Chinese medicine preparation for treating heart failure |
Non-Patent Citations (4)
| Title |
|---|
| 中医对充血性心力衰竭的认识及治疗对策;毛春燕;《河北中医》;20121130;第24卷(第11期);823-824 * |
| 慢性心力衰竭现代治疗进展及中医诊治思路探讨;赵淳等;《中国中医急症》;20060228;第15卷(第2期);158-159 * |
| 毛春燕.中医对充血性心力衰竭的认识及治疗对策.《河北中医》.2012,第24卷(第11期), |
| 赵淳等.慢性心力衰竭现代治疗进展及中医诊治思路探讨.《中国中医急症》.2006,第15卷(第2期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102406754A (en) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101391077A (en) | Preparation method of traditional Chinese medicine for treating chronic pelvic inflammatory disease | |
| CN102274385B (en) | Medicament for treating nasosinusitis and preparation method thereof | |
| CN106266463A (en) | A kind of Chinese medicine composition for treating hyperuricemia and application thereof | |
| CN105250890A (en) | Traditional Chinese medicine for treating hyperlipidemia | |
| CN102406754B (en) | Chinese medicinal composition for treating chronic heart failure | |
| CN102836338B (en) | Chinese medicament for treating cardia-cerebrovascular diseases | |
| CN104840783A (en) | Traditional Chinese medicine preparation for treating urinary calculus and preparation method of traditional Chinese medicine preparation | |
| CN104435545B (en) | A kind of Chinese medicine preparation for treating caused by benzene leukopenia | |
| CN103721053B (en) | A kind of Chinese medicine preparation for the treatment of senile hypothyroidism | |
| CN105749216A (en) | Traditional Chinese medicine wine for treating hypertension and preparation method thereof | |
| CN105456887A (en) | Pharmaceutical for treating aplastic anemia | |
| CN101391019A (en) | Internal medicine for treating breast carcinoma | |
| CN105125814B (en) | It is a kind of to treat chronic renal failure III, the Chinese medicine composition of IV phase | |
| CN104069342A (en) | Traditional Chinese medicine for treating acute heart failure | |
| CN103877383A (en) | Traditional Chinese medicine preparation for treating bronchial asthma with syndrome of intermin-gled phlegm and qi | |
| CN102961612B (en) | Traditional Chinese medicine capsule for treating ankylosing spondylitis | |
| CN103230518A (en) | Traditional Chinese medical composition for treating peptic ulcer | |
| CN108144009A (en) | A kind of Chinese medicine composition for treating coronary heart disease | |
| CN107669836A (en) | Coronary disease and angina pectoris Chinese medicine preparation and preparation method thereof | |
| CN108096484A (en) | A kind of Chinese medicine composition and application for dissection of aorta peri-operation period | |
| CN102671146B (en) | Herbal decoction for curing chronic sinusitis | |
| CN101693095A (en) | Traditional Chinese medicine preparation for treating cirrhosis and liver ascites | |
| CN101249250A (en) | Medicinal liquor preparations for curing stagnation and blood stasis chest stuffiness and pain | |
| CN1246017C (en) | Recipe of medicine for asthma | |
| CN106074784A (en) | The Chinese medicine for the treatment of coronary heart disease and myocardial ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: YANG RUI Free format text: FORMER OWNER: ZHANG JING Effective date: 20130116 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Rui Inventor after: Liu Zhiqiang Inventor after: Ma Shuai Inventor before: Zhang Jing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250021 JINAN, SHANDONG PROVINCE TO: 262500 WEIFANG, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHANG JING TO: YANG RUI LIU ZHIQIANG MA SHUAI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130116 Address after: 262500 Shandong province Qingzhou City Linglong Mountain Road No. 4138 Weifang Yidu Central Hospital Applicant after: Yang Rui Address before: 250021 Ji'nan City, Shandong province by the five weft seven road No. 324 Shangdong Province-owned Hospital Applicant before: Zhang Jing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YANG RUI Effective date: 20140905 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 262500 WEIFANG, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140905 Address after: 226200 chemical industry park, Nantong, Jiangsu, Qidong Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Address before: 262500 Shandong province Qingzhou City Linglong Mountain Road No. 4138 Weifang Yidu Central Hospital Patentee before: Yang Rui |